Current Opinion in Endocrinology and Diabetes was launched in 1994. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of endocrinology and diabetes are divided into 11 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Rosalind S. Brown, MD
Dr Brown graduated from McGill University with First Class Honors in Psychology and received her medical degree from the same institution. She is currently a member of the Endocrine Division at Children's Hospital, Boston where she directs the Clinical Trials Research Program. Dr Brown was formerly Professor of Pediatrics at the University of Massachusetts Medical School, and Director, Division of Pediatric Endocrinology/Diabetes at UMass Memorial Health Center. She has published more than 60 original articles, editorials and book chapters with a special interest in thyroid development and disease and its consequence in childhood and will be a co-Editor of the forthcoming 5th edition of Clinical Endocrinology, a popular textbook in pediatric endocrinology. Dr Brown has been a member of the editorial boards of the Journal of Clinical Endocrinology & Metabolism and Thyroid. Currently, she is a member of the Drug & Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society, the Public Health Committee of the American Thyroid Association, and a member of the American Board of Pediatrics, sub-Board of Pediatric Endocrinology, the examining board in pediatric endocrinology. She recently served on a National Academy of Science committee to evaluate the health implications of perchlorate in the drinking water.
Stephen R. Bloom
Professor Bloom was born in Kent in 1942 and received his undergraduate medical training at Cambridge University. His house officer, senior house officer and registrar posts were largely undertaken at The Middlesex Hospital where he also received his MRC Clinical Research Fellow training. He moved to the Royal Postgraduate Medical School at Hammersmith Hospital in 1974 where his roles have included Senior Lecturer (Consultant Physician), Reader in Medicine, Chairman of the Higher Degrees Committee and Academic Board, Professor of Medicine (Hon Consultant Physician), Director of the Endocrinology Clinical Service and Deputy Director, Department of Medicine, Director of Chemical Pathology (renamed Metabolic Medicine), Chief of Clinical Service Chemical Pathology and Chief of Service Endocrinology and Diabetes. He now holds a dual role as Head of the academic Division of Investigative Science at Imperial College London and as Clinical Director for Pathology and Therapy Services at Hammersmith Hospital responsible for a total budget of £40million annually.
His research work over the years falls into five related categories: endocrinology clinical research, physiology and pathology of gut hormones, control of insulin release and insulin resistance, role of neuropeptides in organ control and the role of neuropeptides in CNS regulation of appetite and related hypothalamic functions. He currently leads a research group investigating hypothalamic appetite control systems and gut hormones. This group's discovery that PYY 3-36 reduces appetite offers a potential new treatment for obesity.
He has published over 1000 papers (excluding review articles) in journals such as Nature, J Biol Chem, PNAS, JCI and NEJM. Steve is also a Director of Thiakis and Chairman Designate of Bioscientifica. In the past Steve has been a member of the Main Scientific Board for AstraZeneca and advisory boards for Upjohn and Novartis.